微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 41.19% | -10.21% | -6.06% | 93/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 43.85% | -6.83% | -5.74% | 88/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 46.52% | 2.34% | 1.55% | 83/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 45.81% | -3.92% | -0.14% | 84/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 45.87% | -8.32% | -2.54% | 84/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 47.07% | -7.19% | 3.55% | 81/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 45.45% | -18.27% | -4.66% | 79/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 47.67% | 1.42% | -4.72% | 83/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 50.04% | 2.27% | -1.34% | 78/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 50.71% | 2.38% | -8.81% | 78/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 55.61% | 16.73% | 18.3% | 62/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 47.01% | -15.13% | -3.92% | 87/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 48.93% | -16.86% | -1.23% | 79/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 49.54% | -16.62% | 3.98% | 81/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 47.64% | -20.93% | -13.99% | 82/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 55.39% | -11.05% | -5.88% | 74/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 58.85% | -9.02% | -0.94% | 58/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 59.41% | -6.27% | -1.4% | 60/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 60.25% | -3.77% | -3.24% | 56/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 62.27% | -6.48% | -3.74% | 60/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 64.69% | -2.46% | 2.06% | 46/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 63.38% | -3.73% | 1.23% | 52/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 62.61% | -6.53% | -5.97% | 44/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 66.58% | -3.36% | 0.4% | 45/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 66.32% | -4.27% | 0.73% | 36/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 65.84% | -4.34% | -1.71% | 39/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 66.98% | -1.31% | -2.78% | 32/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 68.9% | 2.77% | -0.54% | 39/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 69.28% | 2.66% | 0.66% | 28/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 68.82% | 2.14% | 1.39% | 30/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 67.88% | -0.15% | 1.25% | 25/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 67.04% | 2.93% | -0.65% | 40/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 67.48% | 3.84% | 0.15% | 24/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 67.38% | 5.11% | -0.88% | 25/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 67.98% | 5.44% | 4.37% | 26/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 65.13% | -5.66% | 0.22% | 32/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 64.99% | -5.96% | 1.38% | 25/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 64.1% | -9.23% | -0.58% | 23/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 64.47% | -10.21% | -6.62% | 20/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 69.04% | -5.84% | -0.09% | 18/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 69.1% | -6.02% | -2.15% | 13/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 70.62% | -4.49% | -1.65% | 13/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 71.8% | -3.35% | -2.07% | 10/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |